|

Alzheimer's Disease Clinical Trials in Illinois

27 recruiting studies across 1 city

Browse by City

Chicago
27 trials

All Trials in Illinois

Phase
Trial Phase Dist.
Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease StudiesPhase 32 mi
A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's DiseasePhase 32 mi
Characterizing Variability in Hearing Aid Outcomes in Among Older Adults With Alzheimer's DementiaN/A2 mi
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's DiseasePhase 32 mi
Communication Bridge 3 StudyPhase 22 mi
Development of a Database to Investigate Digital and Blood-Based Biomarkers and Their Relationship to Tau and Amyloid PET Imaging in Older Participants Who Are Cognitively Normal (CN), Have Mild Cognitive Impairment (MCI), or Have Mild-to-Moderate AD Dementia—2 mi
A Study of Trontinemab in Participants With Early Symptomatic Alzheimer's DiseasePhase 32 mi
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)Phase 32 mi
Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR VariantPhase 32 mi
Alzheimer's National Registry for Treatment and Diagnostics(ALZ-NET)—2 mi
Feasibility of Using the Gatorade Sports Science Institute (GSSI) Labs App for Hydration Related Outcomes—2 mi
A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-1)Phase 32 mi
Development of a Home Test for Measuring Blood P-tau217 in Alzheimer's Disease Using the Tasso Lancet Device—2 mi
A Study of Donanemab (LY3002813) in Participants Who Completed Study AACM (TRAILBLAZER-ALZ 3-EXT).Phase 32 mi
Central Auditory Processing Modulation Underlying Anxiety Reduction Using Clinically Designed Improvisatory MusicN/A2 mi
Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)Phase 39 mi
Visualizing Brain Proteinopathies Using [F-18]Flornaptitril-PET in the Prediction of Clinical Progression of Mild Cognitive Impairment With Either Suspected Chronic Traumatic Encephalopathy or Alzheimer's DiseasePhase 312 mi
OTC Hearing Aid and MCIN/A12 mi
Trial-Ready Cohort-Down Syndrome (TRC-DS)—14 mi
A Study of a Potential Disease Modifying Treatment in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic MutationPhase 2/314 mi
A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic MutationPhase 2/314 mi
A Study of Zunveyl on Safety, Tolerability, Neuropsychiatric Symptoms, and Caregiver Distress in Alzheimer's Disease (RESOLVE)Phase 416 mi
A Clinical Study of MK-2214 in People With Early Alzheimer's Disease (MK-2214-004)Phase 220 mi
Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's DiseasePhase 235 mi
ACP-204 in Adults With Alzheimer's Disease PsychosisPhase 2/335 mi
A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-2)Phase 335 mi
Late Onset Alzheimer's Disease—37 mi

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.